Please use this identifier to cite or link to this item:
DC FieldValueLanguage
dc.contributor.authorLiu, ZYen_US
dc.contributor.authorAu, MTen_US
dc.contributor.authorHe, TWen_US
dc.contributor.authorYang, Ben_US
dc.contributor.authorLiu, Ben_US
dc.contributor.authorZhang, LMen_US
dc.contributor.authorLuo, CXen_US
dc.contributor.authorRong, LMen_US
dc.contributor.authorWen, CYen_US
dc.identifier.citationBioMed research international, 2019, 2075968, p. 1-6en_US
dc.description.abstractPurpose. Blood vessels and skeleton interact together. Endothelin-1 is a potent vasoconstrictor and also has an effect on bone metabolism. The dual antagonist to both endothelin-1 type A and B receptors, Macitentan, has been approved for clinical management of pulmonary arterial hypertension while little is known about the secondary effect of the drug on spine. We aimed to answer how vertebral bone mass responded to Macitentan treatment in mice.en_US
dc.description.abstractMethods. Sixteen male balb/c mice at 6 months were randomly assigned into 2 groups. Vehicle and Macitentan were administrated via intraperitoneal injection to Control group and Treatment group, respectively, for 4 months. At sacrifice, plasma endothelin-1 was evaluated with ELISA and vertebral bone mass was evaluated with Microcomputed Tomography and histological analysis.en_US
dc.description.abstractResults. We found higher plasma endothelin-1 level (p<0.01) and less vertebral bone mass (p<0.05) in Treatment group compared to controls. Moreover, less osteoblasts and more osteoclasts were observed in the vertebral trabecular bone in the Treatment group compared to controls, by immunohistochemistry of the cell-specific markers.en_US
dc.description.abstractConclusions. Treatment with Macitentan is associated with significant lower vertebral bone mass and therefore the secondary effect of dual antagonists to endothelin-1 receptors on the skeleton should be monitored and investigated in clinical practice. Both osteoblasts and osteoclasts may be involved while the molecular mechanism needs to be further explored.en_US
dc.description.sponsorshipDepartment of Biomedical Engineeringen_US
dc.publisherHindawi Publishing Corporationen_US
dc.relation.ispartofBioMed research internationalen_US
dc.rightsCopyright © 2019 Zhong-Yu Liu et al. This is an open access article distributed under the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en_US
dc.rightsThe following publication Zhong-Yu Liu, Man-Ting Au, Tian-Wei He, et al., “Less Vertebral Bone Mass after Treatment with Macitentan in Mice: A Pilot Study,” BioMed Research International, vol. 2019, Article ID 2075968, 6 pages, 2019 is available at
dc.titleLess vertebral bone mass after treatment with macitentan in mice : a pilot studyen_US
dc.typeJournal/Magazine Articleen_US
dc.description.validate201905 bcrc-
Appears in Collections:Journal/Magazine Article
Files in This Item:
File Description SizeFormat 
Liu_Less_Bone_Vertebral.pdf3.37 MBAdobe PDFView/Open
View full-text via PolyU eLinks SFX Query
Show simple item record
PIRA download icon_1.1View/Download Contents

Page view(s)

Citations as of Feb 19, 2020


Citations as of Feb 19, 2020

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.